The 4 bullish analyst ratings indicate a positive outlook for Sonnet BioTherapeutics. However, the decrease in the average price target from $19.50 to $11.1 suggests that analysts have lowered their expectations for the stock's performance. This could lead to short-term upward pressure on the stock price, but the lowered expectations may also cause some investors to reconsider their positions.